BR112019022308A2 - Método para o tratamento do câncer usando um inibidor bcl-2 junto com um radioimunoterapêutico emissor alfa - Google Patents
Método para o tratamento do câncer usando um inibidor bcl-2 junto com um radioimunoterapêutico emissor alfa Download PDFInfo
- Publication number
- BR112019022308A2 BR112019022308A2 BR112019022308-8A BR112019022308A BR112019022308A2 BR 112019022308 A2 BR112019022308 A2 BR 112019022308A2 BR 112019022308 A BR112019022308 A BR 112019022308A BR 112019022308 A2 BR112019022308 A2 BR 112019022308A2
- Authority
- BR
- Brazil
- Prior art keywords
- cell
- bcl
- venetoclax
- alpha
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762491803P | 2017-04-28 | 2017-04-28 | |
| US62/491,803 | 2017-04-28 | ||
| PCT/US2018/029607 WO2018200841A1 (en) | 2017-04-28 | 2018-04-26 | Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019022308A2 true BR112019022308A2 (pt) | 2020-05-26 |
Family
ID=63919290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019022308-8A BR112019022308A2 (pt) | 2017-04-28 | 2018-04-26 | Método para o tratamento do câncer usando um inibidor bcl-2 junto com um radioimunoterapêutico emissor alfa |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11364235B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4772537A2 (cg-RX-API-DMAC7.html) |
| JP (4) | JP2020517704A (cg-RX-API-DMAC7.html) |
| CN (1) | CN110612109A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019022308A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3059752A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019012660A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018200841A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4772537A2 (en) * | 2017-04-28 | 2026-07-08 | Actinium Pharmaceuticals, Inc. | Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic |
| WO2019094931A1 (en) * | 2017-11-10 | 2019-05-16 | Actinium Pharmaceuticals, Inc. | Combination therapy for treatment of a hematological disease |
| CA3125197A1 (en) * | 2019-01-04 | 2020-07-09 | Actinium Pharmaceuticals, Inc. | Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates |
| TW202131946A (zh) * | 2020-01-10 | 2021-09-01 | 加拿大商融合製藥公司 | 持續性免疫療法 |
| US20240299600A1 (en) * | 2020-09-08 | 2024-09-12 | Actinium Pharmaceuticals, Inc. | Method for treating acute myeloid leukemia using venetoclax in conjunction with lintuzumab-ac225 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4923985A (en) | 1988-05-25 | 1990-05-08 | The United States Of America As Represented By The Department Of Health & Human Services | Process for synthesizing macrocyclic chelates |
| CA2422291C (en) | 2000-09-15 | 2011-03-08 | Sloan-Kettering Institute For Cancer Research | Targeted alpha particle therapy using actinium-225 conjugates |
| US8487131B2 (en) * | 2009-04-15 | 2013-07-16 | Sanford-Burnham Medical Research Institute | Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2) |
| US8546399B2 (en) * | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| JP6831777B2 (ja) * | 2014-07-21 | 2021-02-17 | ノバルティス アーゲー | Cd33キメラ抗原受容体を使用する癌の処置 |
| US10577417B2 (en) | 2014-09-17 | 2020-03-03 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| US20160113925A1 (en) * | 2014-10-22 | 2016-04-28 | Emory University | Methods of treating cancer with a combination of glucose modulators and bcl-2 inhibitors |
| TW201639573A (zh) * | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
| PL3280729T3 (pl) * | 2015-04-08 | 2022-08-22 | Novartis Ag | Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19 |
| WO2017021963A1 (en) * | 2015-08-03 | 2017-02-09 | Biokine Therapeutics Ltd. | Cxcr4 binding agents for treatment of diseases |
| EP4772537A2 (en) * | 2017-04-28 | 2026-07-08 | Actinium Pharmaceuticals, Inc. | Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic |
-
2018
- 2018-04-26 EP EP26175547.4A patent/EP4772537A2/en active Pending
- 2018-04-26 CA CA3059752A patent/CA3059752A1/en active Pending
- 2018-04-26 BR BR112019022308-8A patent/BR112019022308A2/pt unknown
- 2018-04-26 EP EP18792272.9A patent/EP3615047A4/en active Pending
- 2018-04-26 JP JP2019558417A patent/JP2020517704A/ja not_active Withdrawn
- 2018-04-26 US US16/607,168 patent/US11364235B2/en active Active
- 2018-04-26 WO PCT/US2018/029607 patent/WO2018200841A1/en not_active Ceased
- 2018-04-26 CN CN201880027661.XA patent/CN110612109A/zh active Pending
- 2018-04-26 MX MX2019012660A patent/MX2019012660A/es unknown
-
2020
- 2020-07-03 JP JP2020115411A patent/JP2020158544A/ja not_active Withdrawn
-
2022
- 2022-05-16 US US17/745,045 patent/US11844799B2/en active Active
-
2023
- 2023-09-28 JP JP2023168404A patent/JP2023165952A/ja not_active Withdrawn
- 2023-11-02 US US18/500,735 patent/US12133849B2/en active Active
-
2024
- 2024-09-30 US US18/901,169 patent/US20250017919A1/en active Pending
-
2025
- 2025-11-21 JP JP2025202062A patent/JP2026026133A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3059752A1 (en) | 2018-11-01 |
| CN110612109A (zh) | 2019-12-24 |
| US12133849B2 (en) | 2024-11-05 |
| EP3615047A4 (en) | 2021-01-13 |
| WO2018200841A1 (en) | 2018-11-01 |
| US20220273648A1 (en) | 2022-09-01 |
| JP2020158544A (ja) | 2020-10-01 |
| US20250017919A1 (en) | 2025-01-16 |
| US20240131025A1 (en) | 2024-04-25 |
| US11844799B2 (en) | 2023-12-19 |
| US11364235B2 (en) | 2022-06-21 |
| JP2026026133A (ja) | 2026-02-16 |
| EP3615047A1 (en) | 2020-03-04 |
| US20200383974A1 (en) | 2020-12-10 |
| JP2020517704A (ja) | 2020-06-18 |
| EP4772537A2 (en) | 2026-07-08 |
| JP2023165952A (ja) | 2023-11-17 |
| MX2019012660A (es) | 2020-07-27 |
| US20240226095A9 (en) | 2024-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250177494A1 (en) | Methods of cytotoxic gene therapy to treat tumors | |
| Lukas et al. | Immune priming with spatially fractionated radiation therapy | |
| Mallick et al. | Management of glioblastoma after recurrence: A changing paradigm | |
| US12133849B2 (en) | Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha- emitting radioimmunotherapeutic | |
| US12410249B2 (en) | Low dose antibody-based methods for treating hematologic malignancies | |
| WO2020142583A1 (en) | Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates | |
| Chung et al. | A prospective randomized study of gemcitabine with doxifluridine versus paclitaxel with doxifluridine in concurrent chemoradiotherapy for locally advanced pancreatic cancer | |
| Allen | Systemic targeted alpha radiotherapy for cancer | |
| Packer et al. | RETRACTED: Phase 1 study of concurrent RMP‐7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas | |
| Becker et al. | Bevacizumab enhances efficiency of radiotherapy in a lung adenocarcinoma rodent model: role of αvβ3 imaging in determining optimal window | |
| US20230302168A1 (en) | Dr5 radioimmunotherapy in the treatment of solid cancers | |
| US20220008567A1 (en) | Liquidly injectable, self-stabilizing biopolymers for the delivery of radionuclide | |
| HK40018488A (en) | Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic | |
| JP5108781B2 (ja) | 悪性新形成の治療 | |
| Payne et al. | Comparative Efficacy of Alpha and Beta Emitting PSMA-617 Radiopharmaceuticals in a PSMA-Heterogeneous Tumor Model | |
| US20240299600A1 (en) | Method for treating acute myeloid leukemia using venetoclax in conjunction with lintuzumab-ac225 | |
| Kauffman | Preclinical Development of Alpha-Particle Therapeutics | |
| Trivedi et al. | EXTH-44. PERSONALIZED IMMUNOTHERAPY VACCINES FOR GLIOBLASTOMA AND THEIR TREATMENT EFFICACY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |